

1 **SUPPLEMENTARY FIGURE LEGENDS**

2 **Figure S1: Eps8 is localized at focal adhesions and binds directly to FAK**

3 (A) Focal adhesions were isolated from FAK WT and FAK $-/-$ cells using
4 hydrodynamic force. Focal adhesions (solid arrows) were stained with anti-Paxillin
5 pY118 and anti-Eps8. Scale bars: 20 μm . (B) SCC FAK WT and $-/-$ cells were treated
6 with 50 μM blebbistatin for 1 h and then fixed and stained with anti-FAK and anti-
7 Eps8 (left panel) or anti-Src pY416 and anti-Eps8 (right panel). Quantification is
8 representative of three independent experiments. Scale bars: 20 μm . Error bars: s.d. p
9 < 0.001 . SCC FAK WT and $-/-$ cells were treated with 50 μM blebbistatin for 1 h and
10 then fixed and stained with (C) anti-FAK and anti-Eps8, (D) anti-Src pY416 and anti-
11 Eps8 or (E) anti-Paxillin pY118 and anti-Eps8. Colocalization (COSTES r value of
12 five cells) was analyzed using the ImageJ plugin JaCoP (Bolte and Cordelieres,
13 2006). Scale bars: 10 μm (unless otherwise stated).

14

15 **Figure S2: Eps8 is not involved in SCC cell proliferation and random migration,**
16 **but in cancer related processes mediated by FAK**

17 (A) FAK WT and FAK $-/-$ cells were transiently transfected with Eps8 siRNA or (B)
18 infected with Eps8 (shE) or non-targeting (shC) shRNA to stably reduce Eps8 protein
19 expression. Cell proliferation was analyzed by trypan blue staining and cells were
20 counted using the Countess automated cell counter (Life Technologies, Paisley, UK).
21 For random cell migration, SCC FAK WT and $-/-$ cells transiently transfected with
22 Eps8 siRNA were plated sparsely on plastic and random cell migration was recorded
23 over 16 h. (C) Cell velocity, (D) track length and (E) track distance of 30 cells per
24 experiment were analyzed using ImageJ. All experiments were carried out three
25 times. FAK WT and FAK $-/-$ cells were infected with Eps8 (shE) or non-targeting
26 (shC) shRNA to stably reduce Eps8 protein expression. (F) Cells were plated on
27 fibronectin coated coverslips. The confluent cell monolayer was wounded and
28 subsequently fixed and stained with TRITC-phalloidin and anti-GM130. The
29 experiment was repeated at least three times. Solid arrows: polarized cells. Dashed
30 arrows: unpolarized cells. Scale bars: 20 μm . Error bars: s.d. $p < 0.005$. (G) Cells
31 were seeded on growth factor reduced Matrigel. Invasion towards serum gradient > 80
32 μm was analyzed after three days. Error bars: s.e.m. $p < 0.001$. (H) FAK WT and
33 FAK $-/-$ cells with stable knockdown of Eps8 expression were seeded on fibronectin.

1 The cell monolayer was wounded and wound closure was analyzed after 15 h. Error
2 bars: s.e.m. $p < 0.01$. All experiments were carried out at least three times.

3

4 **Figure S3: c-Src-mediated Eps8 tyrosine phosphorylation correlates with Eps8**
5 **localization in SCC FAK $-/-$ cells and Eps8 knockdown reduces the number of**
6 **Src pY416 positive puncta in FAK $-/-$ SCC cells**

7 **(A)** SCC FAK WT and FAK $-/-$ stably infected with Eps8 (shE) or non-targeting
8 shRNA (shC) were treated with 100 nM Dasatinib for 30 min. Cells were lysed and
9 Eps8 was immunoprecipitated using anti-Eps8 antibody, followed by western blotting
10 analysis with the indicated antibodies. Immunoblotting with β -actin served as a
11 loading control. **(B)** FAK $-/-$ cells were grown on coverslips and treated with 100 nM
12 Dasatinib for 24 h. Cells were fixed and stained with anti-Src and anti-Eps8 (left hand
13 panels) or anti-LC3B and anti-Eps8 (right hand panels). Solid arrows indicate
14 peripheral c-Src or Eps8 staining. Dashed arrows indicate internalized c-Src or Eps8
15 staining. Quantitation is representative of three independent experiments. Scale bars:
16 20 μm . Error bars: s.d. $p < 0.001$. Inhibition of active c-Src with 100 nM Dasatinib for
17 24 h was confirmed by western blotting analysis with the indicated antibodies. **(C)**
18 FAK WT and FAK $-/-$ cells were transfected with Eps8 siRNA, fixed 48 h post
19 transfection and stained with anti-paxillin and anti-Src pY416. Results show typical
20 staining observed across multiple experiments. Solid arrows indicate focal adhesions.
21 Dashed arrows indicate internalized active c-Src. Scale bars: 20 μm . FAK WT and
22 FAK $-/-$ cells were infected with Eps8 (shE) or non-targeting (shC) shRNA to stably
23 reduce Eps8 protein expression. Cells were grown on glass coverslips, fixed and
24 stained with **(D)** anti-Src pY416 and anti-Eps8 or **(E)** anti-Src pY416 and anti-
25 paxillin. Results show typical staining observed across multiple experiments. Solid
26 arrows indicate focal adhesions. Dashed arrows indicate internalized active c-Src in
27 autophagosomes. Scale bars: 20 μm . Error bars: s.d. $p < 0.001$.


28

29 **Figure S4: Eps8 is not involved in general autophagy and knockdown of Eps8**
30 **results in loss of actin changes which are not associated with general autophagy**


31 FAK WT and FAK $-/-$ cells were transiently transfected with siEps8 and treated with
32 10 μM chloroquine for 24 h. **(A)** Cells were lysed and samples were subjected to
33 western blot analysis using the indicated antibodies. **(B)** FAK $-/-$ cells, transiently
34 transfected with siEps8 and treated with chloroquine, were fixed and stained with

- 1 anti-LC3B and anti-Src pY416 (left panel) or anti-LC3B and anti-Eps8 (right panel).
- 2 Scale bars: 20 μm . **(C)** SCC FAK $-/-$ cells were transiently transfected with siEps8,
- 3 fixed and stained with anti-Eps8 and TRITC-phalloidin (left panel) and anti-LC3B
- 4 and TRITC-phalloidin (right panel). Scale bars: 20 μm .


Supplementary Figure S1



Supplementary Figure S1 continued





Supplementary Figure S2




Supplementary Figure S2 continued



F



G




H






Supplementary Figure S3

A




B






Supplementary Figure S3 continued

C




Supplementary Figure S3 continued




Supplementary Figure S4

A



B



Supplementary Figure S4 continued

C

